CN1893971A - 用于增强cd8+细胞毒性t细胞应答和用于治疗多发性硬化的方法 - Google Patents

用于增强cd8+细胞毒性t细胞应答和用于治疗多发性硬化的方法 Download PDF

Info

Publication number
CN1893971A
CN1893971A CNA2004800372329A CN200480037232A CN1893971A CN 1893971 A CN1893971 A CN 1893971A CN A2004800372329 A CNA2004800372329 A CN A2004800372329A CN 200480037232 A CN200480037232 A CN 200480037232A CN 1893971 A CN1893971 A CN 1893971A
Authority
CN
China
Prior art keywords
cells
mbp
cell
vaccine
autologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800372329A
Other languages
English (en)
Chinese (zh)
Inventor
Y·C·Q·臧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of CN1893971A publication Critical patent/CN1893971A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/453—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2004800372329A 2003-10-17 2004-10-18 用于增强cd8+细胞毒性t细胞应答和用于治疗多发性硬化的方法 Pending CN1893971A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51221203P 2003-10-17 2003-10-17
US60/512,212 2003-10-17

Publications (1)

Publication Number Publication Date
CN1893971A true CN1893971A (zh) 2007-01-10

Family

ID=34465326

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800372329A Pending CN1893971A (zh) 2003-10-17 2004-10-18 用于增强cd8+细胞毒性t细胞应答和用于治疗多发性硬化的方法

Country Status (10)

Country Link
US (2) US20080107664A1 (cg-RX-API-DMAC7.html)
EP (1) EP1677821B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509063A (cg-RX-API-DMAC7.html)
CN (1) CN1893971A (cg-RX-API-DMAC7.html)
AU (1) AU2004281817B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415519A (cg-RX-API-DMAC7.html)
CA (1) CA2542668C (cg-RX-API-DMAC7.html)
IL (1) IL174935A (cg-RX-API-DMAC7.html)
NZ (1) NZ546552A (cg-RX-API-DMAC7.html)
WO (1) WO2005037309A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102939536A (zh) * 2009-11-14 2013-02-20 匡-宇·邱 用于治疗和/或预防动脉粥样硬化的免疫调节方法和系统
WO2013063713A1 (zh) * 2011-10-31 2013-05-10 鑫品生医科技股份有限公司 诱发产生综合免疫细胞的方法
CN101842478B (zh) * 2007-10-17 2014-04-02 特克赛尔公司 治疗多发性硬化的组合物
CN105085616A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种氨基酸序列及其应用
CN105085615A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种多肽序列及其应用
CN110430886A (zh) * 2017-01-20 2019-11-08 阿塔拉生物制药股份有限公司 使用自体t细胞治疗多发性硬化的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509063A (ja) * 2003-10-17 2007-04-12 ベイラー　カレッジ　オブ　メディスン Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法
ES2553192T3 (es) * 2006-05-05 2015-12-04 Opexa Therapeutics Vacuna de células T
RU2435556C1 (ru) * 2010-04-23 2011-12-10 Владимир Васильевич Лантух Способ лечения дистрофических заболеваний заднего полюса глаза

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680824B2 (en) 1992-04-09 1997-08-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
US6410518B1 (en) * 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
CA2330458A1 (en) 1998-04-29 1999-11-04 Georgetown University Methods of identifying and using hla binding compounds as hla-agonists and antagonists
PT1407004E (pt) * 2001-05-15 2009-08-31 Ortho Mcneil Janssen Pharm Iniciação ex-vivo para produção de linfócitos t citotóxicos específicos de ligando-cd40 para tratar doenças autoimunes e alérgicas
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
JP2007509063A (ja) * 2003-10-17 2007-04-12 ベイラー　カレッジ　オブ　メディスン Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101842478B (zh) * 2007-10-17 2014-04-02 特克赛尔公司 治疗多发性硬化的组合物
CN102939536A (zh) * 2009-11-14 2013-02-20 匡-宇·邱 用于治疗和/或预防动脉粥样硬化的免疫调节方法和系统
WO2013063713A1 (zh) * 2011-10-31 2013-05-10 鑫品生医科技股份有限公司 诱发产生综合免疫细胞的方法
CN105085616A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种氨基酸序列及其应用
CN105085615A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种多肽序列及其应用
CN110430886A (zh) * 2017-01-20 2019-11-08 阿塔拉生物制药股份有限公司 使用自体t细胞治疗多发性硬化的方法

Also Published As

Publication number Publication date
AU2004281817A1 (en) 2005-04-28
BRPI0415519A (pt) 2006-12-26
US20100183546A1 (en) 2010-07-22
EP1677821B1 (en) 2013-02-27
IL174935A (en) 2012-01-31
AU2004281817B2 (en) 2010-07-22
NZ546552A (en) 2009-10-30
CA2542668A1 (en) 2005-04-28
US20080107664A1 (en) 2008-05-08
EP1677821A1 (en) 2006-07-12
CA2542668C (en) 2014-04-29
JP2007509063A (ja) 2007-04-12
IL174935A0 (en) 2006-08-20
WO2005037309A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
Zang et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis
EP1812563B1 (en) Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
Allakhverdi et al. Expression of CD103 identifies human regulatory T-cell subsets
US20100183546A1 (en) Method for Increasing CD8+ Cytotoxic T Cell Responses and for Treating Multiple Sclerosis
JP6000205B2 (ja) Ｔ細胞ワクチン
Venken et al. Memory CD4+ CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens
CN100346824C (zh) 自体t－细胞疫苗材料和方法
TW202208413A (zh) 用於治療多發性硬化症之肽及方法
HK1102914A (en) A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis
WO2008028229A1 (en) Methods of identifying markers
JP2004208548A (ja) 免疫反応の抗原特異的抑制
Ghezzi UNRAVELLING THE ROLE OF MUCOSAL ASSOCIATED INVARIANT T CELLS IN THE PATHOGENESIS OF MULTIPLE SCLEROSIS AND ITS ANIMAL MODEL
Navarro Barriuso Characterization of biomarkers of the generation and functionality of tolerogenic dendritic cells differentiated with vitamin D3
CN1218506A (zh) 对类风湿性关节炎特异的人t细胞克隆
Smith et al. OPEN POSTERS Adhesion molecules
HK1071698B (en) Autologous t-cell vaccines materials and method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1102914

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1102914

Country of ref document: HK